6 hours ago

SELLAS Life Sciences (SLS) Stock Surges Over 200% After Phase 3 Leukemia Vaccine Win

TLDR SELLAS Life Sciences (SLS) stock jumped more than 200% on Tuesday after positive Phase 3 REGAL results. Its cancer vaccine GPS cut the risk of death by 41% in acute myeloid leukemia patients. Median survival was 24.0 months with GPS versus 14.7 months for the control group. The company plans to meet the FDA [...]

The post SELLAS Life Sciences (SLS) Stock Surges Over 200% After Phase 3 Leukemia Vaccine Win appeared first on Blockonomi.

Source: Blockonomi →